Abstract
Ever since its mechanism was discovered back in 2012, the CRISPR/Cas9 system have revolutionized the field of genome editing. While at first it was seen as a therapeutic tool mostly relevant for curing genetic diseases, it has been recently shown to also hold the potential to become a clinically relevant therapy for cancer. However, there are multiple challenges that must be addressed prior to clinical testing. Predominantly, the safety of the system when used for in-vivo therapies, including off-target activity and the effects of the double strand break induction on genomic stability. Here, we will focus on the inherent challenges in the CRISPR/Cas9 system and discuss various opportunities to overcoming these challenges.
Original language | English |
---|---|
Pages (from-to) | 394-402 |
Number of pages | 9 |
Journal | Bioactive Materials |
Volume | 21 |
DOIs | |
State | Published - Mar 2023 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2022 The Authors
Funding
This work was funded by the Shmunis Family Foundation awarded to D.P.
Funders | Funder number |
---|---|
Shmunis Family Foundation |
Keywords
- CRISPR/Cas systems
- Cancer therapy
- Genome editing
- Off-target activity